3rd Quarter - Report

VIROPHARMA INCORPORATED for VIROPHARMA INCORPORATED

Period 3rd Quarter 2012 Filed Oct 22, 2012 Signed by John Greissing, Senior Director, Government Affairs and Health Policy

Official filing
Firm
VIROPHARMA INCORPORATED
Client
VIROPHARMA INCORPORATED
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

340B Drug Pricing Program; Accelerated approval; Antibiotic incentives; Bioequivalence of locally acting drugs; Drug safety/supply chain integrity; Drug shortages; Essential health benefits; Medicaid coverage; Medicare coverage and reimbursement; Orphan Drug Act; Federal grants for drug development; and H.R. 4209, Patients Access to Treatments Act of 2012 (entire bill).

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —

Contacted: Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4209 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.